377 related articles for article (PubMed ID: 18528863)
1. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
2. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
Kobayashi H
Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
[TBL] [Abstract][Full Text] [Related]
3. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
4. cDNA transfection of amino-terminal fragment of urokinase efficiently inhibits cancer cell invasion and metastasis.
Zhu F; Jia S; Xing G; Gao L; Zhang L; He F
DNA Cell Biol; 2001 May; 20(5):297-305. PubMed ID: 11410166
[TBL] [Abstract][Full Text] [Related]
5. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.
Hall WA; Vallera DA
Neurosurg Focus; 2006 Apr; 20(4):E23. PubMed ID: 16709029
[TBL] [Abstract][Full Text] [Related]
7. Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
Lin Y; Yang X; Lu M; Zheng W; Zhang J; Zhuang H; Hua ZC
Anticancer Drugs; 2013 Oct; 24(9):945-57. PubMed ID: 23958791
[TBL] [Abstract][Full Text] [Related]
8. Expression, purification, and biological characterization of the amino-terminal fragment of urokinase in Pichia pastoris.
Li J; Lin Y; Zhuang H; Hua ZC
J Microbiol Biotechnol; 2013 Sep; 23(9):1197-205. PubMed ID: 23751561
[TBL] [Abstract][Full Text] [Related]
9. Modulation of invasive properties of human glioblastoma cells stably expressing amino-terminal fragment of urokinase-type plasminogen activator.
Mohanam S; Chandrasekar N; Yanamandra N; Khawar S; Mirza F; Dinh DH; Olivero WC; Rao JS
Oncogene; 2002 Nov; 21(51):7824-30. PubMed ID: 12420219
[TBL] [Abstract][Full Text] [Related]
10. Suppression of lung tumor growth and metastasis in mice by adeno-associated virus-mediated expression of vasostatin.
Cai KX; Tse LY; Leung C; Tam PK; Xu R; Sham MH
Clin Cancer Res; 2008 Feb; 14(3):939-49. PubMed ID: 18245558
[TBL] [Abstract][Full Text] [Related]
11. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
12. [Experimental study of anti-metastasis effect of urokinase amino-terminal fragment gene on human breast cancer cells].
Zhu F; Xing G; He F
Zhonghua Zhong Liu Za Zhi; 2001 Mar; 23(2):115-7. PubMed ID: 11783013
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor.
Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K
Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid.
Chia JS; Du JL; Hsu WB; Sun A; Chiang CP; Wang WB
BMC Cancer; 2010 Apr; 10():175. PubMed ID: 20429953
[TBL] [Abstract][Full Text] [Related]
15. Vitronectin binding to urokinase receptor in human breast cancer.
Carriero MV; Del Vecchio S; Franco P; Potena MI; Chiaradonna F; Botti G; Stoppelli MP; Salvatore M
Clin Cancer Res; 1997 Aug; 3(8):1299-308. PubMed ID: 9815812
[TBL] [Abstract][Full Text] [Related]
16. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
17. The anti-tumoral potential of the saporin-based uPAR-targeting chimera ATF-SAP.
Zuppone S; Assalini C; Minici C; Bertagnoli S; Branduardi P; Degano M; Fabbrini MS; Montorsi F; Salonia A; Vago R
Sci Rep; 2020 Feb; 10(1):2521. PubMed ID: 32054892
[TBL] [Abstract][Full Text] [Related]
18. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
19. [Construction and activity of recombinant adeno-associated virus expressing vasostatin].
Diao Y; Ma J; Li X; Sun X; Xu R
Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1949-54. PubMed ID: 19256344
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
